Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses.

S M Wood, M E Kraenzlin, T E Adrian, S R Bloom

Seven patients with gut and pancreatic endocrine tumours have been treated with a long acting somatostatin analogue (SMS 201-995), given as a twice daily subcutaneous injection. This produced dramatic improvement in their endocrine related symptoms, in association with a fall in circulating tumour peptides. One of these patients has now been treated for seven months with this analogue which has controlled his previously life threatening diarrhoea caused by a malignant VIP secreting tumour. He gives his own injections twice daily, and has returned to a full and active life. This is a promising agent both for acute treatment of peptide hypersecretion, and for the long term management of some patients who are unresponsive to other available therapy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Chan, N N, Isaacs, A J (1999). Lack of response to octreotide in Cushing's syndrome due to metastatic adrenocortical carcinoma. Postgrad. Med. J. 75: 96-98 [Abstract] [Full Text]  
• Yamada, T., Niinuma, K., Lemaire, M., Terasaki, T., Sugiyama, Y. (1997). CARRIER-MEDIATED HEPATIC UPTAKE OF THE CATIONIC CYCLOPEPTIDE, OCTREOTIDE, IN RATS. Comparison between In Vivo and In Vitro. Drug Metab. Dispos. 25: 536-543 [Abstract] [Full Text]  
• Gorden, P., Comi, R. J., Maton, P. N., Go, V. L. W. (1989). Somatostatin and Somatostatin Analogue (SMS 201-995) in Treatment of Hormone-Secreting Tumors of the Pituitary and Gastrointestinal Tract and Non-Neoplastic Diseases of the Gut. ANN INTERN MED 110: 35-50 [Abstract]  
• Reubi, J.-C. (1987). Somatostatin Receptors as Markers for Endocrine Tumors. JAMA 257: 3277-3277 [Abstract]